To compare Iopamidol injection 370 and Iodixanol 320 in evaluating Neutrophil Gelatinase-Associated Lipocalin (NGAL) in patients with moderate fall in eGFR
This is a pilot study having a randomized, double-blind parallel group comparison of two iodinated contrast agents used during percutaneous coronary intervention (PCI). All patients enrolled must have eGFR greater than or equal to 30 mL/min and less than or equal to 59 mL/min. Statistical summaries will be presented to analyze the various lab tests results for the two groups.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Enrollment
57
Iopamidol 370, one time administration for percutaneous coronary intervention
Iodixanol-320 single administration for percutaneous coronary intervention procedure
Research Cooperative, St. John's Hospital
Springfield, Illinois, United States
UMDNJ - RWJ Medical School
New Brunswick, New Jersey, United States
The Institute for Clinical Research at Holy Name Medical Center
Teaneck, New Jersey, United States
Montreal Heart Institute
Montreal, Quebec, Canada
Impact on the Trajectory of Serum and Urinary Neutrophil Gelatinase-associated Lipocalin (NGAL) Following Administration
Mean change from baseline values for serum NGAL at 2,4,6,24,48, and 72 hours, and urine NGAL at 2,4,6,24, and 48 hours following the administration of contrast media.
Time frame: Baseline and 2, 4, 6, 24, 48,and 72 hours post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.